Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

A man taking Mounjaro as a weight loss drug has explained one of the side effects he's suffering from which 'nobody talks about'.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...